1. Home
  2. CAPR vs IBEX Comparison

CAPR vs IBEX Comparison

Compare CAPR & IBEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • IBEX
  • Stock Information
  • Founded
  • CAPR 2005
  • IBEX 2017
  • Country
  • CAPR United States
  • IBEX United States
  • Employees
  • CAPR N/A
  • IBEX N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • IBEX EDP Services
  • Sector
  • CAPR Health Care
  • IBEX Technology
  • Exchange
  • CAPR Nasdaq
  • IBEX Nasdaq
  • Market Cap
  • CAPR 324.6M
  • IBEX 386.9M
  • IPO Year
  • CAPR N/A
  • IBEX 2020
  • Fundamental
  • Price
  • CAPR $6.18
  • IBEX $37.51
  • Analyst Decision
  • CAPR Strong Buy
  • IBEX Hold
  • Analyst Count
  • CAPR 6
  • IBEX 3
  • Target Price
  • CAPR $23.00
  • IBEX $31.00
  • AVG Volume (30 Days)
  • CAPR 1.0M
  • IBEX 111.1K
  • Earning Date
  • CAPR 11-12-2025
  • IBEX 11-06-2025
  • Dividend Yield
  • CAPR N/A
  • IBEX N/A
  • EPS Growth
  • CAPR N/A
  • IBEX 28.02
  • EPS
  • CAPR N/A
  • IBEX 2.36
  • Revenue
  • CAPR $13,392,150.00
  • IBEX $558,273,000.00
  • Revenue This Year
  • CAPR N/A
  • IBEX $10.15
  • Revenue Next Year
  • CAPR $7,894.07
  • IBEX $5.82
  • P/E Ratio
  • CAPR N/A
  • IBEX $15.92
  • Revenue Growth
  • CAPR N/A
  • IBEX 9.77
  • 52 Week Low
  • CAPR $5.68
  • IBEX $17.53
  • 52 Week High
  • CAPR $22.90
  • IBEX $42.99
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 40.96
  • IBEX 51.92
  • Support Level
  • CAPR $6.05
  • IBEX $36.42
  • Resistance Level
  • CAPR $6.42
  • IBEX $38.50
  • Average True Range (ATR)
  • CAPR 0.34
  • IBEX 0.95
  • MACD
  • CAPR -0.07
  • IBEX -0.11
  • Stochastic Oscillator
  • CAPR 8.95
  • IBEX 63.29

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About IBEX IBEX Limited

IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.

Share on Social Networks: